AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3465375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Prostaglandin F2-alpha
Number of subjects: 45
Study 31447383 — intervention group
Group type: EXPERIMENTAL
Intervention: IIEF-5 score
Number of subjects: 248
Study 31447383 — intervention group
Group type: EXPERIMENTAL
Intervention: AMS score
Number of subjects: 248
Study 31447383 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 61-70
Number of subjects: 248
Study 30249630 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial triple combination therapy with metformin, dapagliflozin, and saxagliptin
Number of subjects: 104
Study 30249630 — intervention group
Group type: COMPARATOR
Intervention: Conventional stepwise add-on therapy
Number of subjects: 104
Study 26767508 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Pillars Immunization Toolkit, early delivery of donated vaccine, staff education, feedback on progress
Number of subjects: 20
Study 26767508 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 20
Study 25162257 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based lifestyle program (Balance after Baby)
Number of subjects: 75
Study 25162257 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 22577186 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit training
Number of subjects: 250
Study 22577186 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy (control)
Number of subjects: 250
Study 20697276 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin (0.3% gatifloxacin ophthalmic solution)
Number of subjects: 44
Study 20697276 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (0.5% moxifloxacin hydrochloride ophthalmic solution)
Number of subjects: 44
Study 20697276 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 44
Study 20697276 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 44
Study 18443573 — intervention group
Group type: EXPERIMENTAL
Intervention: D2 (4 mg/1.25 mg)
Number of subjects: 13
Study 18443573 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 (2 mg/0.625 mg)
Number of subjects: 13
Study 18443573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15977465 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (5 mg daily)
Number of subjects: 50
Study 15977465 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate plus whole-body vibration exercise (ALN+EX)
Number of subjects: 50
Study 14534616 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1‐Ile105/Val105 genotype
Number of subjects: 0
Study 14534616 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygotes for GSTP1 alleles
Number of subjects: 0
Study 10551504 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic electrical stimulation
Number of subjects: 4
Study 8676225 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopy
Number of subjects: 19
Study 8676225 — intervention group
Group type: COMPARATOR
Intervention: Arthrocentesis
Number of subjects: 19
Study 1852179 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (surgical treatment)
Number of subjects: 659
Study 1852179 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical care (control group)
Number of subjects: 659
Study 6822050 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric muscle contractions
Number of subjects: 0
Study 6822050 — intervention group
Group type: COMPARATOR
Intervention: Concentric muscle contractions
Number of subjects: 0
Study 31955956 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypokalemia (<3.0mEq/L)
Number of subjects: 200
Study 31955956 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperkalemia (>6.0mEq/L)
Number of subjects: 200
Study 31955956 — intervention group
Group type: COMPARATOR
Intervention: Normokalemia (3.5-5mEq/L)
Number of subjects: 200
Study 31371391 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic self-assembly process for ion channel clustering; model parameters include nucleation, growth, and removal probabilities; specific channels studied include CaV1.2, CaV1.3, BK, and TRPV4.
Number of subjects: 0
Study 31371391 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer model simulations of channel delivery to membrane; channels delivered at randomly assigned locations.
Number of subjects: 0
Study 31371391 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulating feedback mechanism incorporated in the model.
Number of subjects: 0
Study 28906561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rolapitant (166.5 mg)
Number of subjects: 123
Study 28906561 — intervention group
Group type: COMPARATOR
Intervention: Oral rolapitant (180 mg)
Number of subjects: 123
Study 25600484 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitaminized olive oil (VitVOO)
Number of subjects: 60
Study 25600484 — intervention group
Group type: COMPARATOR
Intervention: Placebo olive oil (PlaVOO)
Number of subjects: 60
Study 24332466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 60
Study 24332466 — intervention group
Group type: COMPARATOR
Intervention: External Fixator
Number of subjects: 60
Study 22505800 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (N = 30)
Number of subjects: 60
Study 22505800 — intervention group
Group type: COMPARATOR
Intervention: No acyclovir (Control, N = 30)
Number of subjects: 60
Study 19120077 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose tacrolimus (target trough levels >10 ng/mL) and corticosteroids; n = 183
Number of subjects: 525
Study 19120077 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2g/day, reduced-dose tacrolimus (target trough levels </=8 ng/mL), and corticosteroids; n = 170
Number of subjects: 525
Study 19120077 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab induction, MMF, reduced-dose tacrolimus delayed until the fifth day posttransplant, and corticosteroids; n = 172
Number of subjects: 525
Study 16881381 — intervention group
Group type: COMPARATOR
Intervention: Oral hormone therapy (HT)
Number of subjects: 88
Study 16881381 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous gel
Number of subjects: 88
Study 16881381 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal patch
Number of subjects: 88
Study 16881381 — intervention group
Group type: EXPERIMENTAL
Intervention: Reservoir patch
Number of subjects: 88
Study 16881381 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix patch
Number of subjects: 88
Study 16881381 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel
Number of subjects: 88
Study 15566133 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound
Number of subjects: 26
Study 15566133 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 26
Study 11342892 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine, aspirin, and ranitidine
Number of subjects: 43
Study 11342892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 9386999 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 5279
Study 9386999 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery
Number of subjects: 5279
Study 9386999 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 5279
Study 9386999 — intervention group
Group type: COMPARATOR
Intervention: Medical morbidity and age
Number of subjects: 5279
Study 7947564 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretor status (determined from saliva samples using a haemagglutination technique)
Number of subjects: 200
Study 7947564 — intervention group
Group type: COMPARATOR
Intervention: Control group (age and sex matched individuals without oral cancer)
Number of subjects: 200
Study 3214944 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 7) increased breastfeeding frequency by 50% after the second menstruation
Number of subjects: 14
Study 3214944 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7) maintained spontaneous feeding pattern
Number of subjects: 14
Study 3214944 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 7)
Number of subjects: 14
Study 3214944 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 14
Study 31595303 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 0
Study 30724760 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-overuse headache (MOH) patients using simple analgesics
Number of subjects: 100
Study 30724760 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-overuse headache (MOH) patients using centrally acting analgesics
Number of subjects: 100
Study 30724760 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-overuse headache (MOH) patients classified as DSM-IV substance dependent
Number of subjects: 100
Study 30724760 — intervention group
Group type: EXPERIMENTAL
Intervention: SDS scores in MOH patients
Number of subjects: 100
Study 30724760 — intervention group
Group type: EXPERIMENTAL
Intervention: SDS scores predicting successful withdrawal
Number of subjects: 100
Study 30724760 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis of SDS scores
Number of subjects: 100
Study 27530911 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric Bypass (GBP)
Number of subjects: 38
Study 27530911 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 38
Study 27530911 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD)
Number of subjects: 38
Study 24906295 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy
Number of subjects: 30
Study 24906295 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study 23279557 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein diet (HP): 32% protein, 41% carbohydrate, 25% fat
Number of subjects: 71
Study 23279557 — intervention group
Group type: COMPARATOR
Intervention: Higher carbohydrate diet (HC): 20% protein, 58% carbohydrate, 21% fat
Number of subjects: 71
Study 21966393 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg/d; n = 105)
Number of subjects: 216
Study 21966393 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (n = 111)
Number of subjects: 216
Study 18838842 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exercise hyperhydration (26 ml of water x kg body mass(‐1) with 1.2 g glycerol x kg body mass(‐1))
Number of subjects: 6
Study 18838842 — intervention group
Group type: COMPARATOR
Intervention: Pre-exercise euhydration
Number of subjects: 6
Study 16808678 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 106
Study 16808678 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine Purite 0.15%
Number of subjects: 106
Study 16808678 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 106
Study 15118290 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally-diluted BCP supplemented with potassium and magnesium (Group M)
Number of subjects: 70
Study 11866251 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone dose reduction with decrease instruction
Number of subjects: 18
Study 11866251 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone dose decrease
Number of subjects: 18
Study 11866251 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance dose
Number of subjects: 18
Study 9834304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary stenting with a Palmaz‐Schatz stent
Number of subjects: 383
Study 9834304 — intervention group
Group type: COMPARATOR
Intervention: Standard balloon angioplasty
Number of subjects: 383
Study 8948744 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with morphine 4 mg and bupivacaine 0.125% 100 ml
Number of subjects: 50
Study 8948744 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCA) with morphine 30 mg and ketorolac 90 mg in 100 ml of saline
Number of subjects: 50
Study 2509059 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin test using RT-23 2 T.U. with Tween 80
Number of subjects: 0
Study 2509059 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitin test prepared from Mycobacterium intracellulare and Mycobacterium kansasii
Number of subjects: 0
Study 2509059 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin reactions to 2 T.U. RT-23 or 5 T.U. P.P.D.
Number of subjects: 0
Study 15943220 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg once daily for 8 weeks
Number of subjects: 114
Study 15943220 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan 20 mg once daily for 8 weeks
Number of subjects: 114
Study 29962366 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 60
Study 29962366 — intervention group
Group type: COMPARATOR
Intervention: Standard community treatment
Number of subjects: 60
Study 28486559 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mindfulness training
Number of subjects: 324
Study 28486559 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 324
Study 25994245 — intervention group
Group type: EXPERIMENTAL
Intervention: Coopdech® laryngoscope
Number of subjects: 107
Study 25994245 — intervention group
Group type: EXPERIMENTAL
Intervention: CoPilot® laryngoscope
Number of subjects: 107
Study 25994245 — intervention group
Group type: COMPARATOR
Intervention: Intubrite® laryngoscope
Number of subjects: 107
Study 25994245 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 107
Study 23453112 — intervention group
Group type: EXPERIMENTAL
Intervention: Open cell stent
Number of subjects: 223
Study 23453112 — intervention group
Group type: COMPARATOR
Intervention: Closed cell stent
Number of subjects: 223
Study 22106080 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual aid
Number of subjects: 89
Study 22106080 — intervention group
Group type: COMPARATOR
Intervention: No visual aid
Number of subjects: 89
Study 22106080 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher literacy levels
Number of subjects: 89
Study 19561485 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted fluid regimen
Number of subjects: 22
Study 19561485 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid regimen
Number of subjects: 22
Study 16690590 — intervention group
Group type: EXPERIMENTAL
Intervention: Low folic acid diet (0 mg/kg)
Number of subjects: 0
Study 16690590 — intervention group
Group type: COMPARATOR
Intervention: Basal folic acid diet (2 mg/kg)
Number of subjects: 0
Study 16690590 — intervention group
Group type: COMPARATOR
Intervention: High folic acid diet (40 mg/kg)
Number of subjects: 0
Study 16690590 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (800 microg/day) in humans
Number of subjects: 0
Study 15364642 — intervention group
Group type: EXPERIMENTAL
Intervention: Aesculus hippocastanum tablets (Aesculaforce 50mg), taken twice daily for 8 weeks.
Number of subjects: 91
Study 11371793 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 169
Study 11371793 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 169
Study 9413588 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoe lift of 1.25 cm added to the left leg
Number of subjects: 20
Study 9413588 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction of limb length discrepancy
Number of subjects: 20
Study 8422221 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 75
Study 8422221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 75
Study 8422221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 3309196 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (4,500 cGy in 5 weeks)
Number of subjects: 510
Study 3309196 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 510
Study 3309196 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 510
Study 31563628 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine paracervical block
Number of subjects: 93
Study 31563628 — intervention group
Group type: COMPARATOR
Intervention: Sham paracervical block
Number of subjects: 93
Study 29797436 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 59
Study 29797436 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) combined with metronidazole (MTZ; 400 mg/TID for 14 days)
Number of subjects: 59
Study 29797436 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) combined with metronidazole (MTZ; 400 mg/TID for 14 days) and amoxicillin (AMX; 500 mg/TID for 14 days)
Number of subjects: 59
Study 27535654 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual pressure applied at the vaccination site for 10 seconds before injection
Number of subjects: 123
Study 27535654 — intervention group
Group type: COMPARATOR
Intervention: Standard injection technique without manual pressure
Number of subjects: 123
Study 24823599 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg, q.d.
Number of subjects: 279
Study 24823599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 23839593 — intervention group
Group type: EXPERIMENTAL
Intervention: Program combining pre-authorization requirement and systematic post-prescription review of carbapenems
Number of subjects: 337
Study 23839593 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 337
Study 20482957 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 267
Study 18201915 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA
Number of subjects: 197
Study 18201915 — intervention group
Group type: COMPARATOR
Intervention: DSA
Number of subjects: 197
Study 16553578 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 14501599 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (10 mg/day testosterone cream)
Number of subjects: 34
Study 11103826 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological therapy, relaxation training, and stress management
Number of subjects: 0
Study 11103826 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial interventions (from a meta-analysis of 23 randomised trials)
Number of subjects: 0
Study 8668779 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed ionic contrast medium with nonsodium pure meglumine as the cation
Number of subjects: 4936
Study 8668779 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed ionic contrast medium with sodium meglumine as the cation
Number of subjects: 4936
Study 8668779 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed nonionic iopamidol
Number of subjects: 4936
Study 8668779 — intervention group
Group type: COMPARATOR
Intervention: Ionic contrast medium at ambient temperature
Number of subjects: 4936
Study 1727784 — intervention group
Group type: EXPERIMENTAL
Intervention: Motilin (10 pmol.kg‐1.min‐1)
Number of subjects: 6
Study 1727784 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 6
Study 6146821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 102
Study 6146821 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg every evening
Number of subjects: 102
Study 31992513 — intervention group
Group type: COMPARATOR
Intervention: AF burden <0.5%
Number of subjects: 30
Study 31992513 — intervention group
Group type: EXPERIMENTAL
Intervention: AF burden ≥0.5%
Number of subjects: 30
Study 30463520 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver gender
Number of subjects: 737
Study 30463520 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient treatment modality
Number of subjects: 737
Study 30463520 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital type
Number of subjects: 737
Study 30463520 — intervention group
Group type: COMPARATOR
Intervention: Reasons for non-participation
Number of subjects: 737
Study 30463520 — intervention group
Group type: COMPARATOR
Intervention: Factors associated with non-participation reasons
Number of subjects: 737
Study 30463520 — intervention group
Group type: COMPARATOR
Intervention: Specific patient characteristics
Number of subjects: 737
Study 30463520 — intervention group
Group type: COMPARATOR
Intervention: Age-related decline reasons
Number of subjects: 737
Study 30463520 — intervention group
Group type: COMPARATOR
Intervention: Burden-related decline reasons
Number of subjects: 737
Study 26197721 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 80
Study 26197721 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 25244479 — intervention group
Group type: EXPERIMENTAL
Intervention: Beat the Blues (BTB) intervention
Number of subjects: 208
Study 25244479 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 208
Study 23185750 — intervention group
Group type: EXPERIMENTAL
Intervention: QM + chemotherapy
Number of subjects: 120
Study 23185750 — intervention group
Group type: COMPARATOR
Intervention: Pure chemotherapy (control group)
Number of subjects: 120
Study 19858256 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 7 mg/kg body weight
Number of subjects: 90
Study 19858256 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 8 mg/kg twice a day
Number of subjects: 90
Study 19858256 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg and 750 mg in healthy adults
Number of subjects: 90
Study 18076245 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 drop jumps (DJs)
Number of subjects: 16
Study 18076245 — intervention group
Group type: COMPARATOR
Intervention: 50 drop jumps (DJs)
Number of subjects: 16
Study 16227840 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin hydrochloride ophthalmic solution, 0.5% - 1 drop every 15 minutes for 4 doses before surgery (group 1)
Number of subjects: 60
Study 16227840 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin hydrochloride ophthalmic solution, 0.5% - 1 drop 4 times per day on the day before surgery plus the same preoperative regimen as group 1 (group 2)
Number of subjects: 60